Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This perimenstrual hormone stabilization intervention is an experimental combination therapy being developed by researchers at the University of Illinois at Chicago (UIC) to treat suicidal ideation in females. The treatment consists of a transdermal estradiol patch (0.1 mg/24 hrs) and oral micronized progesterone (200 mg/day) administered for two weeks starting seven days after ovulation. The mechanism of action involves stabilizing ovarian hormone levels to prevent the acute perimenstrual withdrawal of estradiol and progesterone, which has been linked to increased suicide risk, hopelessness, and hyperarousal in sensitive individuals. This approach is currently being evaluated in the CLEAR-3 (Hormone Stabilization for Proximal Suicide Risk) clinical trial to determine if preventing hormone drops can mitigate proximal suicide risk in reproductive-age females.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol + progesterone (University of Illinois Chicago).